A97 hematology(n= 62), dermatology(n= 14) and psychiatry(n= 72), others(n= 3) from outpatient and inpatient care. The survey consisted of qualitative and quantitative questions covering areas such as the most trusted sources of RWE in Poland, pharma role in RWE generation vs. government's contribution, most desired type of RWE. The questionnaires were collected Sept-Nov 2014 (the total number of responses received n= 251). Data were analyzed using simple descriptive statistics. Results: Physicians demonstrated high degree of interest in evidence on practical outcomes, particularly in data on safety and effectiveness of treatment (over 90% of responders); at the same time 1 out of 5 doctors claimed that data on effectiveness are hardly accessible in Poland. Interesting differences regarding desired real life data were observed across specialties: i.e. treatment pathways and prescribing patterns were frequently valued by diabetologists (87%), while quality of life was often quoted by hematologists (87%). For psychiatrists (69%) data on direct treatment costs are highly important whereas data on patient compliance was most often mentioned by oncologists (79%). ConClusions: The research showed high physicians' interest in practical evidence and the variety of RWE perception. The differences in priorities between specializations indicate unmet needs in therapeutic areas. Broadening doctor's and other stakeholders knowledge in RWE data significance and improving its accessibility could be crucial for gaining doctor's advocacy for shaping RWE landscape in Poland and, consequently, for improving patient's treatment results.
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Is sPatIal segregatIon by Income assocIated wItH self-rePorted dIsabIlIty In cHIle? exPloratory analysIs usIng a PoPulatIon-based survey
Zitko P. 1 , Cabieses B. 2 1 Complejo Asistencial Barros Luco, Santiago, Chile, 2 Universidad del Desarrollo, Santiago, Chile objeCtives: There is limited evidence of the association between spatial segregation by income and health outcomes worldwide. Our objective was to determine crude and adjusted associations between self-reported disability and four measures of spatial segregation by income at individual, household, borough, and health service level in Chile. Methods: Secondary analysis of representative, anonymous CASEN 2009 survey (n= 105,508 of > 20 years age participants from 45,021 households/ 315 boroughs/ 29 health services). The relationship between self-reported disability (physical, sensorial, psychiatric/cognitive) and spatial segregation by income (isolation index, dissimilarity index, Jargowsky coefficient) was explored using 4-level multilevel logistic regression. Control variables were health service´s income inequality (GINI coefficient), age, sex, equivalized household income and educational level. The analysis was stratified by household material poverty (as defined in 2009; around USD$130 per month). Results: Individuals living below the poverty line showed a positive association between spatial isolation and overall and sensorial self-reported disability. However, there was a protective association between spatial isolation and psychiatric/cognitive self-reported disability. Otherwise, people living above the poverty line, showed a positive association between spatial isolation and overall, physical, sensorial and indeed psychiatric/cognitive self-reported disability. Dissimilarity index and Jargowsky coefficient did not show any significant association. Besides, equivalized household income, education, sex and age were important factors associated with self-reported disability, but not for income inequality. ConClusions: Some measures of spatial segregation (isolation) were associated with selfreported disability, even after adjusting for health service´s income inequality and individual-level socio-demographics. These associations may differ depending on the presence of absolute poverty and, hence, further research is urgently required. 2011 and 2013 (N= 12,624) , was used to obtain the self-reported count of chronic conditions (CCs) and BMI. This study included adults 18 years or older living in Puerto Rico with 1 to 6 diagnoses of CCs, and with BMI (kg/m^2) between 20.0 and 45.99. Females that reported pregnancy at time of survey were excluded from analysis. Survey-weighted summary statistics were estimated and Poisson regression coefficients and standard errors (S.E.) calculated using generalized linear models in R. Results: The study population (n= 7,830) represented approximately 1,462,598 adults (55.9%, 95% confidence interval [C.I].: 54.7-57.0). The estimated MCCs prevalence was 56.1% (95% C.I.: 54.7-57.0), whereas the BMI mean was 28.7 kg/m^2 (S.E= 0.08). After adjusting by age, gender, income, smoking status, binge drinking, and high cholesterol the regression model showed that the possibility of reporting more than one chronic condition increases 2.0% (S.E. = 0.16%) with an increment in a BMI unit. The most prevalent combinations of two and three chronic conditions were arthritis-hypertension (10.7%, 95% C.I.: 9.7-11.7), and diabetes-arthritis-hypertension (5.4%, 95% C.I.: 4.7-6.1). ConClusions: Study results suggested that in adults living in Puerto Rico with a chronic condition, the possibility of reporting an additional chronic condition increases as BMI increases. Decision makers should use these findings to support population interventions for weight reduction, policy evaluation, and development of MCC guidelines in an effort to improve quality of life and decrease health care spending. and 9 "No Improvement" by the TC. For 22 "No Benefit" judged by the GBA, 21 were determined "No Improvement" and 1 "Do Not Recommend" by the TC. Of the 26 anti-cancer indications evaluated, similar patterns were observed. Regarding comparators, the TC tended to list multiple whereas the GBA usually used one. In 12 assessments (18%), a completely different comparator was used by the two agencies. ConClusions: While German and French HTA agencies had similar HTA evaluations for a majority of assessments, some differences were noted. Notably, the TC tended to be more restrictive and apply multiple comparators in its HTA evaluations.
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How does a small or medIum sIzed PHarmaceutIcal comPany PrePare for and navIgate tHe scottIsH market? Marshall J. D. , Hill D. , Hill C. A. , Harries M. MAP BioPharma Limited, Cambridge, UK objeCtives: The Scottish Medicines Consortium (SMC) requires all manufactures to submit clinical and economic evidence for products no later than 3 months after licensing. Any products without a submission are automatically not recommended. Due to the complexity of the UK market access environment, small or medium pharmaceutical enterprises (SMEs) may not have the knowledge or resource to generate submissions for all products. In 2015, the SMC aim to improve early engagement with SMEs. To establish the importance of this engagement, we assess the differences in submissions and recommendations between SMEs and larger companies. Methods: Categorizing the top 30 pharmaceutical companies (based on gross revenue) of 2013 as large companies and all other submitting companies as SMEs, SMC recommendations following full, abbreviated or resubmissions were analyzed along with the proportion of non-submissions. Recommendations for co-marketed products were divided evenly between manufacturers. Results: There is a statistically significant relationship between the proportion of positive guidance for large companies and SMEs (75.47% versus 64.62%, p= 0.0002). The number of non-submissions from large companies was 14 in 2012, 18 in 2013 and 8 in 2014; from SMEs the number of non-submissions was 11 in 2012, 7 in 2013 and 6 in 2014. ConClusions: There is a relationship between company size, based on revenue, and likelihood of a positive SMC recommendation, but identification of the cause and effect requires further analysis. These results could indicate that large pharmaceutical companies have a greater influence on the decisions of the SMC, or simply more experience and resource to increase the chances of success. In 2014, the 30 largest companies accounted for more non-submissions than all other pharmaceutical companies, suggesting that large companies can afford to pick and choose whether to submit to the SMC or gain reimbursement through alternative channels whilst avoiding the wider impact of negative guidance.
